Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

InflaRx (NASDAQ:IFRX) reported that IFX-1 missed its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS) patients. HS a chronic inflammatory skin disease that causes abscesses and scarring. IFX-1 is a...

July 19, 2019

Developments

Alphatec launches titanium interbody implant for spinal fusion surgeries

Alphatec Holdings (NASDAQ:ATEC) launched its IdentiTi porous titanium interbody implant system for anterior lumbar interbody fusion procedures. Key features of the implant include a stiffness similar to bone, reduced...

July 19, 2019

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Executive Moves

Soricimed taps industry veteran, Robert Bruce, as CEO

Closely-held Soricimed Biopharma appointed Robert Bruce as CEO, effective immediately, succeeding Paul Gunn, who continues as president. “Soricimed is taking an important step forward at this time and I am excited to...

July 17, 2019

Markets

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...

July 16, 2019

Markets

HCW ups Capricor Therapeutics PT to $12.40 from $3.50

H.C. Wainwright raised its price target for Capricor Therapeutics (NASDAQ:CAPR) to $12.40 from $3.50 after the company posted positive results from an interim analysis of the HOPE-2 trial in patients with Duchenne...

July 16, 2019

Developments

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

The Russian Patent Office issued a notice of acceptance for Theralase Technologies’ (TSXV:TLT) (OTCQB:TLTFF) Multiwavelength photodynamic therapy (PDT) patent application. The patent application will issue into a patent...

July 16, 2019

Developments

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has integrated the i/Blue...

July 15, 2019

Executive Moves

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

David Judd PharmaCyte Biotech (OTCQB: PMCB) appointed David Judd to its medical and scientific advisory board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and...

July 15, 2019

Markets

Roth starts Akero Therapeutics at buy; PT $34

Roth Capital Partners initiated coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and price target of $34. The stock closed at $19.88 on July 12. “Although Akero’s lead asset, AKR-001 (a FGF21...

July 15, 2019

Executive Moves

Rahul Sarugaser joins Raymond James’ life sciences research team

Rahul Sarugaser Rahul Sarugaser has joined Raymond James’ Canadian equity research team as managing director, equity analyst, healthcare, biotechnology & cannabis. Most recently, Mr. Sarugaser was an equities...

July 12, 2019

Markets

Roth resumes coverage of Syros Pharma at buy; PT $17

Roth Capital Partners resumed coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and $17 price target. The stock was quoted at $8.49 in afternoon trading on July 12. Syros was co-founded by ARCH Venture...

July 12, 2019

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

Alphatec launches titanium interbody implant for spinal fusion surgeries

BeyondSpring prices $35-million equity offering

Soricimed taps industry veteran, Robert Bruce, as CEO

HCW starts Precision BioSciences at buy; PT $21

HCW ups Capricor Therapeutics PT to $12.40 from $3.50

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

Imagin Medical updates i/Blue’s functional unit development

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

Roth starts Akero Therapeutics at buy; PT $34

Rahul Sarugaser joins Raymond James’ life sciences research team

Roth resumes coverage of Syros Pharma at buy; PT $17

General

More